Abstract
Introduction
The purpose of the present study was to examine the potential ocular and systemic toxicity and toxicokinetics/pharmacokinetics of sustained-release dexamethasone in canines.
Methods
In this non-randomized study, intracanalicular depots (dexamethasone-loaded or placebo vehicle) were inserted into both eyes of 33 beagles. Tear fluid and plasma were collected for toxicokinetic/pharmacokinetic analysis of dexamethasone, ophthalmic examinations were performed for signs of toxicity, and urine and blood samples were collected for urinalysis, hematology, clinical chemistry, and coagulation analysis. Animals were observed daily for signs of toxicity. Macroscopic and microscopic evaluations were performed.
Results
Mean dexamethasone tear fluid concentration from the dexamethasone group decreased from 4245 ng/mL 6-h post-insertion to 1044 ng/mL on Day 35. All plasma dexamethasone levels were below the limit of quantitation. No systemic or ocular toxicities were attributed to the dexamethasone depot.
Conclusion
Sustained-release dexamethasone produced no identifiable ocular or systemic toxicity in this animal model, and pharmacokinetics demonstrated a tapered, sustained drug release.
Funding
Ocular Therapeutix.
Similar content being viewed by others
References
Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–97.
Vanelli M, Pedan A, Liu N, Hoar J, Messier D, Kiarsis K. The role of patient inexperience in medication discontinuation: a retrospective analysis of medication nonpersistence in seven chronic illnesses. Clin Ther. 2009;31:2628–52.
Kholdebarin R, Campbell RJ, Jin YP, Buys YM. Multicenter study of compliance and drop administration in glaucoma. Can J Ophthalmol. 2008;43:454–61.
Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296–310.
Maxidex [package insert]. Fort Worth, TX: Alcon Laboratories, Inc.; 2007.
An JA, Kasner O, Samek DA. Evaluation of eyedrop administration by inexperienced patients after cataract surgery. J Cataract Refract Surg. 2014;40:1857–61.
Yellepeddi VK, Sheshala R, McMillan H, Gujral C, Jones D, Raghu Raj Singh T. Punctal plug: a medical device to treat dry eye syndrome and for sustained drug delivery to the eye. Drug Discov Today. 2015;20:884–9.
Osbun JW, Ellenbogen RG, Chesnut RM, Chin LS, Connolly PJ, Cosgrove GR, et al. A multicenter, single-blind, prospective randomized trial to evaluate the safety of a polyethylene glycol hydrogel (Duraseal Dural Sealant System) as a dural sealant in cranial surgery. World Neurosurg. 2012;78:498–504.
Cosgrove GR, Delashaw JB, Grotenhuis JA, Tew JM, Van Loveren H, Spetzler RF, et al. Safety and efficacy of a novel polyethylene glycol hydrogel sealant for watertight dural repair. J Neurosurg. 2007;106:52–8.
Takach S, McGrath M, Blizzard C, et al. Influence of storage temperature on sustained release dexamethasone pharmacokinetics in a beagle model. ARVO 2015. Abstract 237-C0092.
Edelman JL. Differentiating intraocular glucocorticoids. Ophthalmologica. 2010;224(Suppl 1):25–30.
Renfro L, Snow JS. Ocular effects of topical and systemic steroids. Dermatol Clin. 1992;10:505–12.
Dexamethasone sodium phosphate [package insert]. Tampa, FL: Bausch & Lomb Incorporated; 2013.
Acknowledgments
Sponsorship and article processing charges for this study were funded by Ocular Therapeutix, Bedford, MA. Editorial assistance in the preparation of this manuscript was provided by Jennifer Klem, Ph.D., of Klem Medical Communications, LLC. Support for this assistance was funded by Ocular Therapeutix, Bedford, MA. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published.
Disclosures
Arthur Driscoll is an employee and equity holder of Ocular Therapeutix. Charles Blizzard is an employee and equity holder of Ocular Therapeutix.
Compliance with Ethics Guidelines
All institutional and national guidelines for the care and use of laboratory animals were followed.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Driscoll, A., Blizzard, C. Toxicity and Pharmacokinetics of Sustained-Release Dexamethasone in Beagle Dogs. Adv Ther 33, 58–67 (2016). https://doi.org/10.1007/s12325-015-0280-7
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-015-0280-7